Abstract:Background Virus-like particles (VLPs) are supramolecular structures composed of multiple protein subunits and resemble natural virus particles in structure and size, making them highly immunogenic materials for the development of next-generation subunit vaccines. The orderly and repetitive display of antigenic epitopes on particle surface allows efficient recognition and cross-link by B cell receptors (BCRs), thereby inducing higher levels of neutralizing antibodies and cellular immune responses than regular subunit vaccines. Here, we present a novel multiple antigen delivery system using SpyCatcher/Spytag strategy and self-assembled VLPs formed by porcine circovirus type 2 (PCV2) Cap, a widely used swine vaccine in solo. Results Cap-SC, recombinant Cap with a truncated SpyCatcher polypeptide at its C-terminal, self-assembled into 26-nm VLPs. Based on isopeptide bonds formed between SpyCatcher and SpyTag, classical swine fever virus (CSFV) E2, the antigen of interest, was linked to SpyTag and readily surface-displayed on SpyCatcher decorated Cap-SC via in vitro covalent conjugation. E2-conjugated Cap VLPs (Cap-E2 NPs) could be preferentially captured by antigen presenting cells (APCs) and effectively stimulate APC maturation and cytokine production. In vivo studies confirmed that Cap-E2 NPs elicited an enhanced E2 specific IgG response, which was significantly higher than soluble E2, or the admixture of Cap VLPs and E2. Moreover, E2 displayed on the surface did not mask the immunodominant epitopes of Cap-SC VLPs, and Cap-E2 NPs induced Cap-specific antibody levels and neutralizing antibody levels comparable to native Cap VLPs. Conclusion These results demonstrate that this modularly assembled Cap-E2 NPs retains the immune potential of Cap VLP backbone, while the surface-displayed antigen significantly elevated E2-induced immune potency. This immune strategy provides distinctly improved efficacy than conventional vaccine combination. It can be further applied to the development of dual or multiple nanoparticle vaccines to prevent co-infection of PCV2 and other swine pathogens.

The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine

Dissolving Microneedle Arrays As a Hepatitis B Vaccine Delivery System Adjuvanted by APC-Targeted Poly (Lactic-Co-glycolic Acid) (PLGA) Nanoparticles

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity

A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

[Impact of Different Adjuvants on Immunogenicity of the HBV Particle Vaccine Containing the S + Pres1 Fusion Antigen in Balb/C Mice].

Folding properties of the hepatitis B core as a carrier protein for vaccination research

Expression and Immunoactivity of Chimeric Particulate Antigens of Receptor Binding Site-Core Antigen of Hepatitis B Virus

Assessing Sequence Plasticity of A Virus-Like Nanoparticle by Evolution Toward A Versatile Scaffold for Vaccines and Drug Delivery

The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Combinatorial Approach to Hepadnavirus-Like Particle Vaccine Design

[The Immunization Effects of HBV Core Antigen and Surface Antigen Fusion Protein in Mice].

Bacterial superglue enables easy development of efficient virus-like particle based vaccines

Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen.

Antigenic analysis of two chimeric hepatitis B core particles presenting the preS1 neutralizing epitopes

Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides

Hepatitis E Virus Capsid As a Carrier of Exogenous Antigens for the Development of Chimeric Virus-Like Particles

Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles

A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture

Chimeric hepatitis B surface antigen virus-like particles expressing the strep A epitope p*17 elicit a humoral immune response in mice